21 May 2021

HAYA Therapeutics SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18m seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.

VISCHER advises Haya Therapeutics SA on all legal issues related to the financing round. The VISCHER team is led by Christian Wyss (Partner, Corporate) with Lukas Züst (Counsel, Corporate) Pauline Pfirter (Associate), Timothy Woodtli (Associate, Corporate), Francesca Pesenti (Associate, Corporate), Gian Geel (Associate, Employment), Adrian Briner (Associate, Tax). 

Press release

Categories: Employment Law, Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Tax

You are currently offline. Some pages or content may fail to load.